$5.85
arrow_drop_down2.33%Key Stats | |
---|---|
Open | $6.03 |
Prev. Close | $5.99 |
EPS | -3.43 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 5.72 | 6.05 |
52 Week Range | 2.30 | 14.24 |
Ratios | |
---|---|
EPS | -3.43 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, RVNC, BALY, DRQ on Behalf of Shareholders
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Revance Therapeutics, Inc. – RVNC
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR)
Revance Therapeutics (RVNC) Loses -18.85% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
These Analysts Lower Their Forecasts On Revance Therapeutics After Q1 Results
Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Lags Revenue Estimates